---
title: "MediciNova: Differentiated NAFLD/MASH Profile and Complementary APOC3 Positioning Support Unchanged $6 Target and Buy Rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293670592.md"
description: "Maxim Group analyst Jason McCarthy maintained a Buy rating and $6 price target for MediciNova. He cited the company's differentiated NAFLD/MASH profile and MN-001's multi-mechanistic approach as complementary to APOC3 therapies, rather than competitive. The upcoming Phase 2 readout in mixed populations is highlighted as a key catalyst. Additionally, H.C. Wainwright also maintained a Buy rating with a $10 price target."
datetime: "2026-07-23T21:25:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293670592.md)
  - [en](https://longbridge.com/en/news/293670592.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293670592.md)
---

# MediciNova: Differentiated NAFLD/MASH Profile and Complementary APOC3 Positioning Support Unchanged $6 Target and Buy Rating

Medicinova, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $6.00 price target.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Jason McCarthy has given his Buy rating due to a combination of factors tied to MediciNova’s differentiated profile in metabolic disease. He notes that recent Phase 3 success by Arrowhead in severe hypertriglyceridemia validates APOC3 biology and the commercial potential of triglyceride-lowering therapies, while simultaneously underscoring that triglyceride reduction alone does not address liver fat or liver enzyme abnormalities.

In this context, MN-001’s oral, multi-mechanistic approach, which has shown the ability to lower both triglycerides and liver fat and to raise HDL in a diabetic NAFLD population, positions it for a potentially broader role in NAFLD/MASH with coexisting hypertriglyceridemia and type 2 diabetes. McCarthy also highlights the upcoming Phase 2 readout in this mixed population as a key catalyst and argues that MN-001 is complementary rather than directly competitive to APOC3 agents, supporting his unchanged $6 price target and Buy recommendation.

McCarthy covers the Healthcare sector, focusing on stocks such as Medicinova, Inmune Bio, and AIM ImmunoTech. According to TipRanks, McCarthy has an average return of \-13.0% and a 30.06% success rate on recommended stocks.

In another report released on July 15, H.C. Wainwright also maintained a Buy rating on the stock with a $10.00 price target.

### Related Stocks

- [MNOV.US](https://longbridge.com/en/quote/MNOV.US.md)
- [ARWR.US](https://longbridge.com/en/quote/ARWR.US.md)
- [INMB.US](https://longbridge.com/en/quote/INMB.US.md)
- [AIM.US](https://longbridge.com/en/quote/AIM.US.md)
- [4875.JP](https://longbridge.com/en/quote/4875.JP.md)
- [AIMID.US](https://longbridge.com/en/quote/AIMID.US.md)
- [AIMI.US](https://longbridge.com/en/quote/AIMI.US.md)

## Related News & Research

- [Analyst Reiterates Buy on MediciNova as Advancing Pipeline and Upcoming ALS Catalysts Support Unchanged $6 Price Target](https://longbridge.com/en/news/291454858.md)
- [Mark Mahaney Initiates Buy on Lime, Citing Undervalued Cash Flow Potential and Upside to $40 Price Target](https://longbridge.com/en/news/293847311.md)
- [Jefferies Keeps Their Buy Rating on Schlumberger (SLB)](https://longbridge.com/en/news/293848420.md)
- [15:53 ETAstaReal® Astaxanthin Demonstrates Performance-Multiplying Benefits Through Enhanced Metabolic Efficiency](https://longbridge.com/en/news/294251743.md)
- [12:05 ETAqua Medical Treats First U.S. Patient for Type 2 Diabetes at UNC Health Using Investigational Through-The-Scope Endoscopic Therapy](https://longbridge.com/en/news/294091337.md)